You are here

Vascular & Endovascular

 

The FDA approved the AngioJet ZelanteDVT thrombectomy catheter on Nov. 30 to treat patients with deep vein thrombosis. The catheter also received a CE Mark on the same day for approval in Europe.

 

Recent Headlines

Teaming Up to Tackle Stroke

A few years ago at a conference for heart disease survivors, two well-known cardiologists fielded questions about stroke.

Resetting the Clock: Stent Retrievers & the Race to Stop Stroke

“Time is brain,” physicians say. As they ponder new data on acute stroke intervention with stent retrievers, many are advocating for new systems and a team-based approach modeled after the successful door-to-balloon time protocols that have vastly improved heart attack outcomes.

FDA recalls catheters used in drainage sets

The FDA recalled the catheter included in the Fuhrman Pleural/Pneumopericardial Drainage Set, which is used to remove air from the pericardium surrounding the heart or drain fluid from the pleural cavity that protects the lungs.

ACC launches data registry for left atrial appendage occlusion devices

The American College of Cardiology (ACC) launched a registry on Dec. 16 to track data on left atrial appendage occlusion (LAAO) devices.

ACC, SCAI, HRS release consensus statement on left atrial appendage occlusion requirements

Three leading cardiology societies released a consensus statement on Dec. 10 regarding criteria institutions and operators should follow for left atrial appendage occlusion.

FDA approves thrombectomy catheter to treat deep vein thrombosis

The FDA approved the AngioJet ZelanteDVT thrombectomy catheter on Nov. 30 to treat patients with deep vein thrombosis. The catheter also received a CE Mark on the same day for approval in Europe.

AHA.15: Watchman device is safe at 30 days in real-world registry

After 30 days of follow-up, 92.7 percent of patients with atrial fibrillation at high-risk for stroke who were implanted with the Watchman device did not have any serious adverse events, according to an analysis of an international registry. In addition, 98.5 percent of patients had a successful implantation, which was defined as deployment and release of the device into the left atrial appendage.

Reverse Course: NOAC Antidotes Poised to Allay Bleeding Concerns

The stars appear to be aligned for drugs that reverse the effect of novel oral anticoagulants (NOACs). Regulators in the U.S. have moved them forward, anxious to provide emergency physicians an antidote in cases of life-threatening bleeding. But the ultimate beneficiaries may be patients who need but don’t take anticoagulants because of bleeding fears.

Researchers identify molecule that may help patients recover after strokes

Researchers discovered a molecule that may be a potential therapy for patients recovering from a stroke. The molecule, known as growth and differentiation factor 10 (GDF10), is activated early after stroke, according to researchers from the department of neurology at the University of California, Los Angeles.

Stent retrievers make Cleveland Clinic’s top 10 medical innovations for 2016

As part of its annual Medical Innovation Summit, the Cleveland Clinic released its top 10 medical innovations for 2016. The list of the technologies that will have the biggest impact in healthcare included neurovascular stent retrievers, which are used after patients suffer an ischemic stroke.

Pages